OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Richter on Early Abnormalities Indicative of a Multiple Myeloma Diagnosis

April 15th 2025

Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Dr Tykodi on the Selection Between IO/IO and IO/TKI Combinations in Frontline Advanced Clear Cell RCC

April 15th 2025

Scott Tykodi, MD, PhD, discusses key clinical considerations that informing selection between IO/IO and IO/TKI combinations in advanced renal cell carcinoma.

Dr Mateos on the Future Clinical Development of Cilta-Cel in Myeloma

April 15th 2025

María-Victoria Mateos, MD, PhD, discusses the future clinical development of ciltacabtagene autoleucel in multiple myeloma.

Dr Nguyen on Treatment Selection Considerations for Non–Clear Cell RCC

April 15th 2025

Charles B. Nguyen, MD, details treatment selection in clinical practice for patients with non–clear cell renal cell carcinoma.

Dr Hernández-Boluda on the Rationale for Using Machine Learning to Predict Post-HCT Outcomes in Myelofibrosis

April 14th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.

Dr Choi on Advances With Cell Therapy in Hematologic Malignancies

April 14th 2025

Yeong “Christopher” Choi, PhD, MBA, discusses the importance of developing biomedical technologies for hematologic malignancies and other diseases.

Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC

April 14th 2025

Xiaojia Wang, MD, shares responses achieved with the combination of ivonescimab plus chemotherapy in locally advanced unresectable or metastatic TNBC.

Dr Abu Rous on the Identification of Clinically Actionable Biomarkers in Squamous Cell Carcinoma of the Lung

April 14th 2025

Fawzi F Abu Rous, MD, discusses the need for reliable predictive biomarkers for therapeutic development in squamous cell carcinoma of the lung.

Dr Ghia on the Role of Fixed-Duration Ibrutinib Plus Venetoclax in CLL and Beyond

April 14th 2025

Paolo Ghia, MD, PhD, discusses ongoing and future directions for the investigation of fixed-duration ibrutinib/venetoclax in CLL.

Dr Lee on the Preliminary Safety of Nivolumab for Resectable dMMR Endometrial Cancer

April 14th 2025

Yong Jae Lee, MD, PhD, discusses the clinical relevance of the preliminary safety of nivolumab for resectable mismatch repair–deficient endometrial cancer.

Dr Tarantino on the Evolving Role of Anthracycline- and Taxane-Based Regimens in HER2+ Breast Cancer

April 12th 2025

Paolo Tarantino, MD, discusses the evolving role of anthracycline- and taxane-based regimens in HER2-positive breast cancer.

Dr Cortese on Methods for Evaluating immunologic Changes With Venetoclax in CLL

April 11th 2025

Matthew Cortese, MD, MPH, discusses the methods used to produce a comprehensive map of immune changes that occur with venetoclax treatment in CLL.

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

April 11th 2025

Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.

Dr He on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable/Metastatic HCC

April 11th 2025

Aiwu Ruth He, MD, PhD, discusses the significance of data from the CheckMate 9DW trial evaluating frontline nivolumab plus ipilimumab in metastatic HCC.

Dr Saxena on the Evolving Utility of Targeted Therapies for ALK+ NSCLC

April 11th 2025

Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.

Dr Lopetegui-Lia on Adjuvant Therapy for Early-Stage TNBC With Residual Disease

April 11th 2025

Nerea Lopetegui-Lia, MD, discusses treatment options for patients with chemotherapy-pretreated early-stage high-risk TNBC with residual disease at surgery.

Dr Somaiah on Overcoming Challenges to Multidisciplinary Approaches in Sarcoma

April 11th 2025

Neeta Somaiah, MD, details challenges that are associated with pathology diagnosis, NGS, and early opinions for patients with sarcomas.

Aguilar-Clancy on the Importance of Individualized Nutritional Support as a Component of Oncology Care

April 11th 2025

Claudia Aguilar Clancy, FNP-C, AOCNP, discusses the importance of individualized nutritional support as a component of oncology care.

Dr Kozek on Oncology Nurses’ Perceived Difficulties in Providing Palliative Care to Adult Patients

April 11th 2025

Caroline Kozek, DNP, RN, AGNP-C, OCN, discusses a study assessing oncology nurses’ perceived difficulties in providing palliative care to adult patients.